Smoking cessation drug led to almost a third of smokers quitting during phase III trial
Participants taking cytisinicline in the ORCA-2 study had a higher abstinence rate from smoking than those assigned to placebo.
In those taking the drug for 12 weeks, 33% of participants were abstinent during weeks 9 to 12, compared with 7% taking placebo
Shutterstock.com
A smoking cessation drug that could be the first newly approved treatment for nearly 20 years saw almost a third of users quit smoking at one point during a phase III trial.
Get unlimited access to all content
You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.
